Ligand Pharmaceuticals | LGND - Los Gastos De Explotación





Los Gastos De Explotación Cambio Fecha
Agenus USD -199.08M 22.15M 2026-06
Amgen USD 11.69B 6.9B 2026-06
Anika Therapeutics USD 137.28M 3.38M 2026-06
Arrowhead Research USD 245.35M 30.35M 2026-06
Baxter International USD 2.68B 3.36B 2026-06
Bristol-Myers Squibb USD 22.32B 2.25B 2026-06
Eli Lilly USD 10.52B 496M 2026-06
Enanta Pharmaceuticals USD 126.59M 346.51M 2025-12
Enviri Corporation USD 233.18M 357.11M 2026-03
Gilead Sciences USD 3.95B 19.57B 2026-06
GlaxoSmithKline GBP 5.8B 468M 2026-06
Glaxosmithkline GBP 5.34B 3.83B 2026-03
Heron Therapeutics USD 40.55M 1.46M 2025-12
Insmed USD 526.79M 20.55M 2026-06
Intrexon USD 61.56M 26.1M 2024-06
Ionis Pharmaceuticals USD 370.24M 6.24M 2026-06
Karyopharm Therapeutics USD 61.83M 9.9M 2026-03
Ligand Pharmaceuticals USD 55.1M 20.75M 2026-06
MacroGenics USD 42.87M 21.68M 2026-06
Merck USD 15.77B 2.4B 2026-06
Pacira USD 180.54M 7.79M 2026-06
Pfizer USD 85.19B 4.91B 2026-06
Rigel Pharmaceuticals USD 117.61M 35.67M 2025-09
Sangamo BioSciences USD 33.87M 12.89M 2024-06
Veracyte USD 126.36M 6.37M 2026-06